HUNTINGTON BEACH, California and AMSTERDAM, Feb. 4 /CNW/ - Agendia, a
world leader in molecular cancer diagnostics, today announced that its
signature breast cancer test MammaPrint(R) will be offered as standard of care
for all eligible early stage breast cancer patients at the Netherlands Cancer
Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL). The NKI-AVL believes
MammaPrint provides better guidance for decisions regarding adjuvant therapy.
As one of the participating centers in the MINDACT trial NKI-AVL is already
offering MammaPrint to patients and will continue to do so. In future,
however, NKI-AVL will also make MammaPrint available to patients who fall
outside MINDACT's inclusion criteria.
"We are very pleased that MammaPrint will become available for all
eligible breast cancer patients at the NKI-AVL hospital," said Bernhard Sixt,
Ph.D., president and chief executive officer of Agendia. "The NKI-AVL is a
worldwide acknowledged center of excellence and a leading institution in
advancing cancer treatment and care. Agreements with other hospitals and the
recent inclusion of MammaPrint in the updated 2008 clinical practice
guidelines of CBO, the Dutch Institute for Healthcare Improvement, ensure that
an ever increasing number of breast cancer patients can rely on MammaPrint."
MammaPrint is the first 'in vitro diagnostic multivariate index assay'
(IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance
requires clinical and analytical validation and reporting systems to ensure
patient safety issues are addressed. Highly accurate, MammaPrint identifies
patients with early metastasis - those patients who are likely to develop
metastases within five years following surgery. Several authoritative studies
have shown that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test result provides a doctor with a clear
rationale to assess the benefit of adjuvant chemotherapy in addition to other
clinical information and pathology tests.
All MammaPrint tests are conducted in Agendia's CLIA-certified service
laboratory. All other breast cancer recurrence assays currently marketed have
not been subject to the rigorous FDA clearance process.
Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatments within reach of
patients. Building on a cutting edge genomics platform for tumor gene
expression profiling, the company's tests aim to help physicians more
accurately tailor cancer treatments. The company markets four products, with
several new genomic tests under development. In addition, Agendia collaborates
with pharmaceutical companies to develop highly effective personalized drugs
in the area of oncology. Agendia is based in Huntington Beach, California, and
in Amsterdam, The Netherlands. For more information please visit
For further information:
For further information: MEDIA CONTACTS: Hans Herklots, Head of
Corporate Communications, +31-20-462-1557 Office, +31-620-083-509 Cell,
email@example.com; Valerie Delva, Ricochet Public Relations, (212)
679-3300 x131 Office, (917) 975-3191 Cell, firstname.lastname@example.org